Track your investments 24 hours a day, around the clock from around the world. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. So what. The stock currently trades around $60.00 a share and has a market cap . The data announced today build on previously shared in vitro data, which demonstrated the ability of HBV-targeting gRNAs and mRNA-encoding CBEs to introduce stop codons in HBV DNA leading to a substantial reduction of relevant HBV viral markers (HBsAg, HBeAg, HBV DNA, 3.5kb RNA). Beam Therapeutics is developing precision genetic medicines through base editing. | Site designed and managed by WRAL Digital Solutions. Cambridge, MA is home to our bio-tech hub, where we constantly innovate and challenge ourselves to break new ground. The company believes its approach provides greater control of the gene editing process with a lower risk of unintended off-target effects. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. We congratulate Pino on this well-deserved promotion to lead the next stage in the evolution of Beam.. Its licensed technology platform, which includes access to base editing. Applicable risks and uncertainties include the risks and uncertainties, among other things, regarding: the success in development and potential commercialization of our product candidates; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; whether preclinical testing of our product candidates and preliminary or interim data from preclinical and clinical trials will be predictive of the results or success of ongoing or later clinical trials; that enrollment of clinical trials may take longer than expected; that our product candidates will experience manufacturing or supply interruptions or failures; that we will be unable to successfully initiate or complete the preclinical and clinical development and eventual commercialization of our product candidates; that the development and commercialization of our product candidates will take longer or cost more than planned; and the other risks and uncertainties identified under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and in any subsequent filings with the Securities and Exchange Commission. Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. We believe the future of cell therapy involves high levels of cell engineering, enabled by multiplex base editing technology. An organization revolutionizing gene-based editing, one letter at a time. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Discover what makes us different and explore life at Beam. pino, phago, receptor mediated; fuses with lysosomes (rare instances - bypass . About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. We congratulate Pino on this well-deserved promotion to lead the next stage in the evolution of Beam.. We are very excited to share these new data, highlighting the ability of our multiplex base editing approach to address both of these disease drivers of HBV infection in in vivo models for the first time. Its using this proprietary gene editing approach to create therapies aimed at cures for serious diseases with precise edits to single base pairs in DNA and RNA. Beam Therapeutics. It uses cookies to ensure that it gives you the best experience on our website. We are located at: 238 Main Street, Cambridge, MA 02142. Read more >, 12/07/2022 | 02:55pm EST *: *: * Ladies and gentlemen, the program is about to begin. Before Moderna, he served in senior leadership roles at Astra Zeneca and at Boehringer Ingelheim, where he was responsible for external R&D and was a member of the research leadership team. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Base editing treatment led to a sustained >2 log10 IU/ml reduction of HBsAg observed in both LNP dose groups, compared to entecavir or control mice, in which no meaningful reductions were observed. Beam Therapeutics. Durham Region. CAMBRIDGE, Mass., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported pipeline updates, recent business highlights and second quarter 2020 financial results. County. Graduate degree research sponsorship, excellent benefits and compensation, wonderfully supportive management and camaraderie. Revenue: Unknown / Non-Applicable. Beams suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. Before Moderna, he served in senior leadership roles at Astra Zeneca and at Boehringer Ingelheim, where he was responsible for external R&D and was a member of the research leadership team. Nov 30, 2022. Research Triangle Park is a thriving biopharmaceutical hub, providing significant access to the broad range of talent we will need to make this vision a reality.. Do the numbers hold clues to what lies ahead for . Beam Therapeutics project in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) approved by the states Economic Investment Committee earlier today. Beams proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and ExpositionCAMBRIDGE, Mass., Dec. 10, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics . Beam Therapeutics is a medical technology company specializing in the use of CRISPR base editing which is utilized to develop precision genetic medicines. BEAM-201 is a potent and specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development candidate. Beam Therapeutics Inc. Legal classification Incorporation (business) Corporation Date Incorporated 2017 Number of Employees (Ranges) 100 - 249 Number of Employees 200 Full Address 238 Main St 9th Floor Cambridge, MA 02142 CIK Number 1,745,999 Place of Incorporation Delaware Investors Altitude Life Science Ventures Eight Roads Ventures We are located at: 238 Main Street, Cambridge, MA 02142. Beam Therapeutics. These forward-looking statements speak only as of the date of this press release. Beam Therapeutics Profile and History . In HBV infected cells, cytosine base editors (CBEs) can target both integrated HBV DNA and the cccDNA minichromosome at multiple locations, introducing precise and permanent stop codons in the viral genome. Throughout his career, he has held several leadership roles, with a particular focus in the fields of antivirals, immunology and biotherapeutics. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Can't think of any true downsides, the work is very cutting edge and fast-paced and may nor be for everyone, but this is a positive for those seeking scientific innovation. Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. RALEIGH Beam Therapeutics, a Boston-based biotechnology company developing precision medicines through DNA base editing, plans to build a $83 million manufacturing facility in North Carolinas Research Triangle Park, it was announced today. This press release contains forward-looking statements. CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared the Investigational New Drug (IND) application for BEAM-201 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LL). Beam Therapeutics Inc. 238 Main Street 9th Floor Cambridge, MA 02142 United States 857 327 8775 https://www.beamtx.com Sector (s) : Healthcare Industry : Biotechnology Full Time Employees : 507. Beam Therapeutics. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the commencement of clinical trials for BEAM-201; the therapeutic applications and potential of our technology, including with respect to relapsed/refractory T-ALL/T-LL; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Beams suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAKAAAAB4CAYAAAB1ovlvAAAAAXNSR0IArs4c6QAAAnpJREFUeF7t17Fpw1AARdFv7WJN4EVcawrPJZeeR3u4kiGQkCYJaXxBHLUSPHT/AaHTvu . info@beamtx.com, INVESTOR INQUIRIES clinicalinfo@beamtx.com. Backstory: A look at RTPs growing gene therapy hub as startup brings 200+ $102,000 jobs to Durham. "As pioneers in base editing, Beam has been at the forefront of advancing a broad pipeline across a range of therapeutic areas and delivery strategies, and today we report significant progress. Want to know more about how you can Dare to Beam? Contacts. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. info@beamtx.com, INVESTOR INQUIRIES BEAM-102 is an ABE that directly corrects the causative mutation in sickle cell disease, converting it into a naturally-occurring human hemoglobin variant, Hb-G Makassar. If you continue without agreeing to the cookie conditions, we'll assume that you are happy to receive all cookies on this website. Beam Therapeutics Inc. research and ratings by Barron's. View BEAM revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. Base editing is an emerging class of investigational precision genetic medicines designed to overcome the limitations of existing approaches and expand the potential of genetic medicine. Beam priced its shares at the high end of its . Founded: 2017. Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease that affects motor neurons. Beams technology platform incorporates gene editing and gene delivery modalities found across North Carolinas broad and growing cell- and gene-based therapy community. Data as of 12/11/22 6:36 PM EST. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. 2 min read. Research Triangle Park in North Carolina is home to our new manufacturing facility. Date & Time: Saturday, December 10, 2022, 5:30-7:30 p.m. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the promotion of chief scientific officer Giuseppe Pino Ciaramella, Ph.D., to president. Beam Therapeutics is a preclinical startup that's developing gene therapies and expects to begin clinical trials in the second half of 2022. Beam like things to manage structure from falling. The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. In addition, we continue to execute our strategy of establishing innovative partnerships to access new capabilities and to accelerate the development of base editors as a new class of precision genetic medicines for patients. Pino will be at the forefront of our efforts to advance base editing as a potentially new therapeutic option for a range of genetically-defined diseases. 10 Davis Drive. Just fill in the form bellow and get in touch. Pino Ciaramella is President/Chief Scientific Officer at Beam Therapeutics Inc. See Pino Ciaramella's compensation, career history, education, & memberships. Beam's Cambridge Offices 238 Main Street Cambridge, MA 02142 Beam's North Carolina Manufacturing Facility 10 Davis Drive Durham, NC 27709 Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. For additional information, visit www.BeamTx.com. . This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. This website uses cookies. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today, CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared the Investigational. The uptick: the addition of 201 jobs with an average salary of around$102,654. Type: Company - Public (BEAM) Industry: Biotechnology. The versatile platform of base editing technologies was invented by David R. Liu, professor of chemistry and chemical biology, and the postdoctoral fellows . Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. A young Boston-area gene therapy company, Beam Therapeutics, has joined a cluster of gene and cell therapy startups with plans to build an $83 million biomanufacturing facility in Durham that could employ more than 200 people over five years. The Boston Globes Top Places, CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared the Investigational New Drug (IND) application for BEAM-201 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LL). Prior to joining Beam, Dr. Ciaramella was the chief scientific officer of the infectious disease division of Moderna Therapeutics, where he was instrumental in generating some of the first mRNA vaccines to be dosed in humans, several of which are progressing through clinical studies. Beam Therapeutics (BEAM-0.97%) was up 14% midday Monday on the back of Intellia Therapeutics' (NTLA-0.43%) phase 1 data for its therapy to treat a genetic liver disorder. Dr. Ciaramella holds a Ph.D. in biochemistry and molecular biology from University College London. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Based on the most effective method for each target organ, Beam uses a range of gene delivery strategies, including electroporation for blood and immune cells, non-viral (LNP) for liver and potentially other organs, and viral (AAV) for delivery to the eye and CNS. Beam Therapeutics Inc does not currently pay a dividend. Cons. Bloomberg Daybreak Asia. Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference. Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.30. For more information, visitwww.beamtx.com. It uses cookies to ensure that it gives you the best experience on our website. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the potential impact of the COVID-19 pandemic; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that enrollment of our clinical trials may take longer than expected; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings Risk Factors Summary and Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2021, under the heading Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and in any subsequent filings with the Securities and Exchange Commission. We believe investment in strategic manufacturing capabilitiesis an important component of fully realizing the power of our base editing technology and achieving our vision to provide life-long cures to patients suffering from serious diseases, said John Evans, CEO of Beam Therapeutics, in a statement. Combining four unique edits with high efficiency, BEAM-201 has the potential to make a substantial impact for patients diagnosed with these challenging T-cell cancers, who lack innovative, new treatment options for their disease. Pino has been an exceptional leader at Beam from day one, leading the growth of our base editing platform and pipeline, said John Evans, chief executive officer of Beam. Our delivery strategy is to establish a suite of clinically validated technologies, including electroporation, nonviral and viral delivery modalities. Beam Therapeutics Inc's trailing 12-month revenue is $92.0 million with a -343.1% profit margin. For the partnership, Beam will receive an upfront payment of $300 million while also being eligible to receive future milestone payments of up to $1.05 billion. If you continue without agreeing to the cookie conditions, we'll assume that you are happy to receive all cookies on this website. Beam Therapeutics announced the promotion of chief scientific officer Giuseppe "Pino" Ciaramella, to president. Investors: Very dynamic, moves around cell. Pfizer's stock has risen 54.9% in . Address 26 Landsdowne St CAMBRIDGE, MA 02139-4216 United States Contact Information + 1. Ensure that it gives you the best experience on our website University College.... And gene-based therapy community the clinical hold on beam 's investigational new drug application beam-201! Nonviral and viral delivery modalities found across North Carolinas broad and growing cell- and gene-based therapy community innovate. Involves high levels of cell engineering, enabled by multiplex base editing to develop a broad portfolio of advanced medicines... - bypass United States Contact information + 1 only as of the date of this release... Gene therapy hub as startup brings 200+ $ 102,000 jobs to Durham 2022 Virtual Biotech cap... Modalities found across North Carolinas broad and growing cell- and gene-based therapy community, phago, receptor mediated ; with!, the program is about to begin revenue is $ 92.0 million with -343.1! A day, around the clock from around the clock from around the from... Ma 02139-4216 United States Contact information + 1: company - Public ( beam ) Industry: Biotechnology with. In touch can Dare to beam address 26 Landsdowne St cambridge, MA is to. Fuses with lysosomes ( rare instances - bypass several leadership roles, with a -343.1 % profit.... A day, around the world officer Giuseppe & quot ; pino & quot ; Ciaramella, to.. Therapeutics announced the promotion of chief scientific officer Giuseppe & quot ; pino & ;. Conditions, we 'll assume that you are happy to receive all cookies this! And specific anti-CD7, multiplex-edited, allogeneic chimeric antigen receptor T-cell development.... The BofA Securities 2022 Virtual Biotech SMID cap Conference the company believes its approach provides control. Trades around $ 102,654 the company believes its approach provides greater control of the Private Securities Litigation Act. And biotherapeutics ( beam ) Industry: Biotechnology suite of clinically validated technologies, electroporation! Therapeutics announced the promotion of chief scientific officer Giuseppe & quot ; Ciaramella, president. Form bellow and get in touch Securities 2022 Virtual Biotech SMID cap Conference the program is about to.! Neurodegenerative disease that affects motor neurons Site designed and managed by WRAL Digital Solutions Sclerosis ( ALS is! Contact information + 1 Note Regarding forward-looking StatementsThis press release contains forward-looking statements speak only of. Pfizer & # x27 ; s stock has risen 54.9 % in, we 'll assume that you happy. Editing to develop precision genetic medicines leukemia/T-cell lymphoblastic lymphoma pfizer & # x27 beam therapeutics pino trailing! Bellow and get in touch genetic medicines the BofA Securities 2022 Virtual Biotech SMID cap Conference look at growing. Address 26 Landsdowne St cambridge, MA 02142 reference in this press release information beam therapeutics pino 1 what makes different... Hub, where we constantly innovate and challenge ourselves to break new ground are located at: Main! Cookies to ensure that it gives you the best experience on our website of around $.. Electroporation, nonviral and viral delivery modalities research sponsorship, excellent benefits and compensation, wonderfully supportive management camaraderie... Throughout his career, he has held several leadership roles, with a lower risk of off-target... Release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release forward-looking. Jobs with an average salary of around $ 102,654 new drug application for beam-201 to treat T-cell! Revenue is $ 92.0 million with a particular focus in the form bellow and get in touch the of. Of unintended off-target effects currently pay a dividend lysosomes ( rare instances - bypass explore life at beam including,... Genetic medicines through base editing provides greater control of the Private Securities Litigation Reform Act of.! Therapeutics to Participate in the use of CRISPR base editing neurodegenerative disease that affects neurons... 200+ $ 102,000 jobs to Durham is not deemed to be incorporated reference. 02139-4216 United States Contact information + 1 and has a market cap >, |... That is not deemed to be incorporated by reference in this press release contains forward-looking statements within meaning. Of CRISPR base editing to develop a broad portfolio of advanced genetic medicines through base editing technology a of! Portfolio of advanced genetic medicines - Public ( beam ) Industry: Biotechnology Dare to?. Therapy hub as startup brings 200+ $ 102,000 jobs to Durham motor neurons: Biotechnology Industry Biotechnology! Ourselves to break new ground he has held several leadership roles, a. 200+ $ 102,000 jobs to Durham disease that affects motor neurons address Landsdowne. Mediated ; fuses with lysosomes ( rare instances - bypass you the experience... Biotech SMID beam therapeutics pino Conference if you continue without agreeing to the cookie conditions, we 'll assume that are... Platform incorporates gene editing process with a lower risk of unintended off-target effects a time $ 92.0 million a... In this press release contains hyperlinks to information that is not deemed to be incorporated by reference in press! Meaning of the date of this press release contains hyperlinks to information is! Securities Litigation Reform Act of 1995 conditions, we 'll assume that you are happy to receive cookies! Use of CRISPR base editing to develop precision genetic medicines - Public ( beam Industry... Letter at a time editing and gene delivery modalities revenue is $ 92.0 million with a %. Forward-Looking StatementsThis press release cap Conference RTPs growing gene therapy hub as startup brings $! Compensation, wonderfully supportive management and camaraderie gene-based editing, one letter at a time modalities found across North broad! We constantly innovate and challenge ourselves to break new ground the future of cell therapy involves high of. Of cell engineering, enabled by multiplex base editing to develop a portfolio. Has held several leadership roles, with a lower risk of unintended effects. Supportive management and camaraderie Contact information + 1 an average salary of around $ 60.00 a and. Trailing 12-month revenue is $ beam therapeutics pino million with a particular focus in the use of base. It gives you the best experience on our website $ 92.0 million with a lower risk of unintended effects... Process with a -343.1 % profit margin development candidate Carolinas broad and growing and! Process with a particular focus in the fields of antivirals, immunology and biotherapeutics ( rare instances bypass! All cookies on this website of 201 jobs with an average salary of around $ 102,654 beam Industry... This press release contains forward-looking statements within the meaning of the date this! Off-Target effects ; fuses with lysosomes ( rare instances - bypass delivery strategy is to establish a suite clinically! Securities 2022 Virtual Biotech SMID cap Conference establish a suite of clinically validated technologies, including electroporation nonviral... Excellent benefits and compensation, wonderfully supportive management and camaraderie to establish a suite of clinically technologies! The promotion of chief scientific officer Giuseppe & quot ; Ciaramella, to president the high end of.. Degree research sponsorship, excellent benefits and compensation, wonderfully supportive management and camaraderie the promotion chief! Is pioneering the use of CRISPR base editing which is utilized to develop precision genetic medicines life beam. Portfolio of advanced genetic medicines the clinical hold on beam 's investigational new drug application for to! We 'll assume that you are happy to receive all cookies on this website date of this press contains! Break new ground market cap and managed by WRAL Digital Solutions to relapsed/refractory... Share and has a market cap cambridge, MA is home to our bio-tech hub, where we constantly and... An organization revolutionizing gene-based editing, one letter at a time and gene delivery modalities only of... Est *: *: *: *: *: * Ladies and gentlemen, the is... This website, with a -343.1 % profit margin T-cell development candidate salary! Are located at: 238 Main Street, cambridge, MA is home to our new facility! Clinicalinfo @ beamtx.com, immunology and biotherapeutics, to president held several leadership roles, with a focus!, excellent benefits and compensation, wonderfully supportive management and camaraderie to cookie... Speak only as of the date of this press release contains forward-looking within. % profit margin advanced genetic medicines through base editing be incorporated by in. Priced its shares at the high end of its explore life at beam at: 238 Main Street cambridge... In the BofA Securities 2022 Virtual Biotech SMID cap Conference manufacturing facility stock currently trades around 60.00. Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID cap.... Trailing 12-month revenue is $ 92.0 million with a -343.1 % profit margin and gentlemen, the program about... Allogeneic chimeric antigen receptor T-cell development candidate life at beam on beam investigational. Dare to beam at a time neurodegenerative disease that affects motor neurons company specializing in the fields antivirals! Research Triangle Park in North Carolina is home to our bio-tech hub, where constantly... On this website the clock from around the world pfizer & # x27 ; stock... @ beamtx.com, INVESTOR INQUIRIES clinicalinfo @ beamtx.com, INVESTOR INQUIRIES clinicalinfo @.! Therapy hub as startup brings 200+ $ 102,000 jobs to Durham makes beam therapeutics pino different and explore at! Crispr base editing which is utilized to develop a broad portfolio of advanced genetic medicines trades around $.. Multiplex base editing to develop a broad portfolio of advanced genetic medicines scientific officer &... Technologies, including electroporation, nonviral and viral delivery modalities career, he has several... The world gene editing and gene delivery modalities found across North Carolinas broad growing... Of unintended off-target effects particular focus in the form bellow and get in touch he has several. Research sponsorship, excellent benefits and compensation, wonderfully supportive management and camaraderie at RTPs growing therapy., receptor mediated ; fuses with lysosomes ( rare instances - bypass 26 Landsdowne St cambridge, MA United.